“duchenne-muscular-dystrophy” Archives

in
Entry Author Date Location
After Sarepta’s Surprising FDA Nod, CEO Kaye Plans to Resign 04/28/17 Boston
Duchenne, SMA, and the Rise of Patient Power at “What’s Hot” on May 11 04/27/17 Boston
Bristol Flips Remnants of Adnexus, iPierian to Roche, Biogen For $470M 04/13/17 New York
Bio Roundup: New Drug Bonanza, Vertex’s Triple Play, CAR-T Race & More 03/31/17 National
Bio Roundup: Trumpcare Wavers, Amgen Courts Payers, Critics Circle PTC 03/24/17 National
Sanders, Cummings to PTC: Price Duchenne Steroid at Import Cost 03/22/17 New York
After a Clinical Trial Death, FDA OKs New Tests of Akashi’s Duchenne Drug 03/22/17 Boston
For $140M, PTC Gets Duchenne Drug and a Pricing Controversy from Marathon 03/16/17 New York
First Trial in Sight, Editas Cuts $90M Eye Drug Deal With Allergan 03/14/17 Boston
Biotech Roundup: Obamacare Lite, DePinho Out, Dunsire In & More 03/10/17 National
Nonprofit Seeds Exonics to Fund Push For CRISPR Duchenne Treatment 02/27/17 Boston
Cashing in On Duchenne Approval, Sarepta Sells Voucher to Gilead For $125M 02/21/17 Boston
Bio Roundup: CRISPR Drama, Marathon and PhRMA, the Price of Vision & More 02/17/17 National
His Gene Therapy Near Approval, Spark CEO Wonders: What Price Vision? 02/16/17 New York
CEO Kaye Details Insurance Battle As Sarepta Launches Duchenne Drug 01/10/17 Boston
Families Fret As Insurers Mull Biogen’s $750K Spine Disease Drug 01/06/17 National
Biogen Sets $750,000 Initial Price For First-Ever Spinal Atrophy Drug 12/28/16 Boston
Bio Roundup: Drug Pricing, Cystic Fibrosis Showdown, Myovant & More 10/28/16 National
Bio Roundup: Jenkins Gets Mad, Bernie Gets His Pen, CRISPR IPO & J-Lo 10/21/16 National
Defying Patient Pressure, Anthem Says No to Sarepta’s Duchenne Drug 10/07/16 Boston
Bio Roundup: Theranos Cuts, Alnylam Stops, Nobel Eats Its Own & More 10/07/16 National
Exact Sciences, Rockwell, & Gender Gaps: This Week’s WI Watchlist 10/04/16 Wisconsin
Post FDA Approval, Sarepta Wheels and Deals for Combo Duchenne Drugs 10/04/16 Boston
Bio Roundup: CAR-T & Migraine Races, Intra-Cellular, Rockefeller & More 09/30/16 National
Bio Execs Talk Patient Advocacy, Duchenne Approval at BioForward Panel 09/28/16 Wisconsin
Sarepta Preps For Sales As Insurers Unlikely To Deny Duchenne Drug 09/22/16 Boston
Sarepta Prices $300K Duchenne Drug As FDA Rift Emerges Over Approval 09/19/16 Boston
After New Data, FDA Bucks Advisory Panel, Approves Sarepta’s Duchenne Drug 09/19/16 Boston
Biotech Roundup: CRISPR’s 3rd IPO, Gender Diversity, Buyouts & More 09/16/16 National
Seeking to Join Editas, Intellia, CRISPR Tx Makes Long Awaited IPO Push 09/12/16 Boston
Page 1 of 5 next page »